Alastair Matheson, independant consultant and former ghostwriter, describes how the pharmaceutical publications industry seeks to legitimise ghostwriting by changing its definition while deflecting attention from wider marketing practices in academic publishing.
Read his full analysis:
http://www.bmj.com/content/354/bmj.i4578
